Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Receives Consensus Recommendation of “Hold” from Brokerages

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS – Get Free Report) has received a consensus rating of “Hold” from the eleven analysts that are presently covering the firm, Marketbeat.com reports. Eight investment analysts have rated the stock with a hold recommendation, two have given a buy recommendation and one has issued a strong buy recommendation on the company. […]

Leave a Reply

Your email address will not be published.

Previous post NeuroPace (NASDAQ:NPCE) Price Target Raised to $14.00 at JPMorgan Chase & Co.
Next post Digihost Technology’s (DGHI) Buy Rating Reiterated at HC Wainwright